🔎 Trials Near Me

Akèy › Obèsite › Tennessee › Knoxville

Etid klinik pou Obèsite nan Knoxville, TN

10 etid pou Obèsite ap chèche patisipan nan sit nan ak bò kote Knoxville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Ap rekriteFaz 3
  • New Phase Research and Development, Knoxville
  • Accellacare US Inc., d/b/a Accellacare of Knoxville, Knoxville
Laj 18 a 99 · Tout sèks · Mizajou Oct 5, 2026 · NCT07684235

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Ap rekriteFaz 3
  • Accellacare of Knoxville, Knoxville
  • Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell · 8 mi lwen
Laj 45 a 99 · Tout sèks · Mizajou Oct 5, 2026 · NCT07037433

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Ap rekriteFaz 2
  • New Phase Research & Development /ID# 282131, Knoxville
  • Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07752979

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Ap rekriteFaz 3
  • Research Site, Knoxville
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Ap rekriteFaz 3
  • Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell · 8 mi lwen
  • Parkway Cardiology Associates, Oak Ridge · 20 mi lwen
Laj 18 a 99 · Tout sèks · Mizajou Sep 16, 2026 · NCT07037459

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Ap rekriteFaz 3
  • ACCOMPLISH-1 Research Site, Knoxville
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361

Daily Eating Patterns for Total Health Study

Ap rekrite
  • Healthy Eating and Activity Laboratory, Knoxville
Laj 25 a 60 · Tout sèks · Mizajou Jun 15, 2026 · NCT06455995

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Ap rekriteFaz 1
  • MBX Biosciences Investigational Site, Knoxville
Laj 18 a 65 · Tout sèks · Mizajou Jun 9, 2026 · NCT07142707

EBT Fruit and Vegetable Prescription

Ap rekriteVolontè an sante akeyi
  • Cherokee Health Systems, Dameron Avenue Pedatrics, Knoxville
Laj 4 a 10 · Tout sèks · Mizajou Jun 9, 2026 · NCT05028205

Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia

Ap rekriteEtid obsèvasyon
  • University of Tennessee Medical Center, Knoxville
Laj 18 a 45 · Fanm · Mizajou Sep 10, 2025 · NCT06802861

Etid Obèsite nan lòt vil

Lòt etid nan Knoxville

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.